Avidity Biosciences, Inc. (RNA)
NASDAQ: RNA · Real-Time Price · USD
72.90
+0.04 (0.05%)
Feb 20, 2026, 11:37 AM EST - Market open
Avidity Biosciences Revenue
Avidity Biosciences had revenue of $12.48M in the quarter ending September 30, 2025, with 434.03% growth. This brings the company's revenue in the last twelve months to $20.87M, up 106.27% year-over-year. In the year 2024, Avidity Biosciences had annual revenue of $10.90M with 13.99% growth.
Revenue (ttm)
$20.87M
Revenue Growth
+106.27%
P/S Ratio
526.08
Revenue / Employee
$53,371
Employees
391
Market Cap
10.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.90M | 1.34M | 13.99% |
| Dec 31, 2023 | 9.56M | 336.00K | 3.64% |
| Dec 31, 2022 | 9.22M | -102.00K | -1.09% |
| Dec 31, 2021 | 9.33M | 2.54M | 37.41% |
| Dec 31, 2020 | 6.79M | 4.47M | 192.67% |
| Dec 31, 2019 | 2.32M | 1.94M | 511.87% |
| Dec 31, 2018 | 379.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.16B |
| BioMarin Pharmaceutical | 3.09B |
| Exelixis | 2.32B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Ionis Pharmaceuticals | 966.96M |
| Madrigal Pharmaceuticals | 740.64M |
| Axsome Therapeutics | 561.26M |
RNA News
- 1 day ago - The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - PRNewsWire
- 17 days ago - Avidity Biosciences Announces Expected Record Date for Spin-Off - PRNewsWire
- 21 days ago - Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance - Seeking Alpha
- 22 days ago - Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development - Accesswire
- 5 weeks ago - Pharma sector doubles down on AI amid hopes of slashing costs, timelines - Reuters
- 2 months ago - Top 2 Health Care Stocks That May Keep You Up At Night In December - Benzinga
- 3 months ago - These 15 stocks are still showing momentum — and a market-beating edge - Market Watch
- 3 months ago - Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 - PRNewsWire